Application of PBPK modeling to elucidate factors that limit systemic exposure

This case study illustrates how information such as bioavailability (F), fraction absorbed (Fabs ) and fraction surviving gut metabolism (Fg ) generated from a clinical study, can aid development and validation of a PBPK model, which can help formulation design and decision making during clinical development.